# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate...
Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients w...